ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.2480dup (p.Asn827fs) (rs397507286)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000130443 SCV000185307 pathogenic Hereditary cancer-predisposing syndrome 2017-08-23 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000031368 SCV000300524 pathogenic Breast-ovarian cancer, familial 2 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
GeneDx RCV000381040 SCV000329134 pathogenic not provided 2018-01-22 criteria provided, single submitter clinical testing This duplication of one nucleotide in BRCA2 is denoted c.2480dupA at the cDNA level and p.Asn827LysfsX3 (N827KfsX3) at the protein level. Using alternate nomenclature, this variant would be defined as BRCA2 2708dupA. The normal sequence, with the base that is duplicated in braces, is GAAA[A]TTAT. The duplication causes a frameshift, which changes an Asparagine to a Lysine at codon 827, and creates a premature stop codon at position 3 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. We consider this variant to be pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000550883 SCV000694608 likely pathogenic Hereditary breast and ovarian cancer syndrome 2016-01-22 criteria provided, single submitter clinical testing Variant summary: c.2480dupA variant causes a frameshift, which alters the proteins amino acid sequence beginning at position 827 and leads to a premature termination codon 2 amino acids downstream. It is predicted to cause a truncated or absent BRCA2 protein. Heterozygous loss-of-function due to mutations in this gene is an established disease mechanism in HBOC. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. p.Gln2859fs). This variant was not found in approximately 120450 chromosomes from the broad and large populations from ExAC. To our knowledge, this variant has not been reported in affected patients via literature, nor evaluated by functional studies. One clinical lab and one reputable database have classified this variant as pathogenic. Taken together, this variant has currently been classified as likely pathogenic until more information becomes available.
Invitae RCV000550883 SCV000635224 pathogenic Hereditary breast and ovarian cancer syndrome 2018-08-03 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Asn827Lysfs*3) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with BRCA2-related disease. ClinVar contains an entry for this variant (Variation ID: 37787). Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). For these reasons, this variant has been classified as Pathogenic.
Sharing Clinical Reports Project (SCRP) RCV000031368 SCV000053973 pathogenic Breast-ovarian cancer, familial 2 2009-06-09 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.